OncoMatch/Clinical Trials/NCT06600698
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Is NCT06600698 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies INM176 for prostate cancer.
Treatment: INM176 — This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: surgery
Post-radical prostatectomy (RP)
Must have received: radiation therapy
post-radiation therapy (RT)
Must have received: antiandrogen
previous use of antiandrogen therapy
Lab requirements
Blood counts
Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count ≥ 1.0 x 10^9/L. INR, PT, and PTT within normal institutional limits
Kidney function
Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Chronic kidney disease with calculated GFR <30 mL/min/1.73 m2 using Cockcroft-Gault formula, or measured GFR <30 mL/min/1.73 m2 using a 24-hour urine collection [excluded]
Liver function
Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN)
Subjects must have normal liver and kidney function at baseline: Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN). Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Adequate bone marrow function: Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count of ≥ 1.0 x 10^9/L). International Normalized Ratio (INR), Prothrombin Time (PT), and Partial Thromboplastin Time (PTT) within normal institutional limits.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Penn State Cancer Institute · Hershey, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify